Cargando…
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies
Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an internation...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366686/ https://www.ncbi.nlm.nih.gov/pubmed/33491094 http://dx.doi.org/10.2340/00015555-3751 |
_version_ | 1784765621273100288 |
---|---|
author | DE BRUIN-WELLER, Marjolein BIEDERMANN, Tilo BISSONNETTE, Robert DELEURAN, Mette FOLEY, Peter GIROLOMONI, Giampiero HERCOGOVÁ, Jana HONG, Chih-Ho KATOH, Norito PINK, Andrew E. RICHARD, Marie-Aleth SHUMACK, Stephen SILVESTRE, Juan F. WEIDINGER, Stephan |
author_facet | DE BRUIN-WELLER, Marjolein BIEDERMANN, Tilo BISSONNETTE, Robert DELEURAN, Mette FOLEY, Peter GIROLOMONI, Giampiero HERCOGOVÁ, Jana HONG, Chih-Ho KATOH, Norito PINK, Andrew E. RICHARD, Marie-Aleth SHUMACK, Stephen SILVESTRE, Juan F. WEIDINGER, Stephan |
author_sort | DE BRUIN-WELLER, Marjolein |
collection | PubMed |
description | Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an international Steerng Committee, spanning 3 areas (Guiding Principles, Decision Making, and Outcome Thresholds) and 2 specific time-points; an initial acceptable target at 3 months and an optimal target at 6 months, each based on improvements in patient global assessment plus at least one specific outcome domain. These treat-to-target-orientated recommendations were evaluated by an extended international panel of physicians, nurses and patients. Proposed recommendations were rated using a 9-point Likert scale; for each recommendation, consensus agreement was reached if ≥ 75% of all respondents rated agreement as ≥ 7. Consensus on 16 core recommendations was reached over 2 eDelphi rounds. These provide a framework for shared decision-making on systemic treatment continuation, modification, or discontinuation. |
format | Online Article Text |
id | pubmed-9366686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Society for Publication of Acta Dermato-Venereologica |
record_format | MEDLINE/PubMed |
spelling | pubmed-93666862022-10-20 Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies DE BRUIN-WELLER, Marjolein BIEDERMANN, Tilo BISSONNETTE, Robert DELEURAN, Mette FOLEY, Peter GIROLOMONI, Giampiero HERCOGOVÁ, Jana HONG, Chih-Ho KATOH, Norito PINK, Andrew E. RICHARD, Marie-Aleth SHUMACK, Stephen SILVESTRE, Juan F. WEIDINGER, Stephan Acta Derm Venereol Clinical Report Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an international Steerng Committee, spanning 3 areas (Guiding Principles, Decision Making, and Outcome Thresholds) and 2 specific time-points; an initial acceptable target at 3 months and an optimal target at 6 months, each based on improvements in patient global assessment plus at least one specific outcome domain. These treat-to-target-orientated recommendations were evaluated by an extended international panel of physicians, nurses and patients. Proposed recommendations were rated using a 9-point Likert scale; for each recommendation, consensus agreement was reached if ≥ 75% of all respondents rated agreement as ≥ 7. Consensus on 16 core recommendations was reached over 2 eDelphi rounds. These provide a framework for shared decision-making on systemic treatment continuation, modification, or discontinuation. Society for Publication of Acta Dermato-Venereologica 2021-02-17 /pmc/articles/PMC9366686/ /pubmed/33491094 http://dx.doi.org/10.2340/00015555-3751 Text en © 2021 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license |
spellingShingle | Clinical Report DE BRUIN-WELLER, Marjolein BIEDERMANN, Tilo BISSONNETTE, Robert DELEURAN, Mette FOLEY, Peter GIROLOMONI, Giampiero HERCOGOVÁ, Jana HONG, Chih-Ho KATOH, Norito PINK, Andrew E. RICHARD, Marie-Aleth SHUMACK, Stephen SILVESTRE, Juan F. WEIDINGER, Stephan Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies |
title | Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies |
title_full | Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies |
title_fullStr | Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies |
title_full_unstemmed | Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies |
title_short | Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies |
title_sort | treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies |
topic | Clinical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366686/ https://www.ncbi.nlm.nih.gov/pubmed/33491094 http://dx.doi.org/10.2340/00015555-3751 |
work_keys_str_mv | AT debruinwellermarjolein treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT biedermanntilo treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT bissonnetterobert treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT deleuranmette treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT foleypeter treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT girolomonigiampiero treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT hercogovajana treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT hongchihho treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT katohnorito treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT pinkandrewe treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT richardmariealeth treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT shumackstephen treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT silvestrejuanf treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies AT weidingerstephan treattotargetinatopicdermatitisaninternationalconsensusonasetofcoredecisionpointsforsystemictherapies |